July 28, 2017 10:35 AM EDT
Pharma

Biotech bil­lion­aire Soon-Sh­iong picks up rights to CytRx’s trou­bled can­cer drug

John Carroll

Editor & Founder

A year ago shares of CytRx $CYTR were crushed by the fail­ure of its lone drug al­dox­oru­bicin to beat physi­cian’s choice in treat­ing soft …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Re­gen­eron makes $80M obe­si­ty deal with Han­soh

Phase 3 or bust: Why Lil­ly won't run mid-stage can­cer tri­als

Bris­tol My­ers bets $1.5B on BioN­Tech's PD-L1xVEGF from Bio­theus

Sanofi to snap up Blue­print Med­i­cines and mas­to­cy­to­sis drug Ay­vak­it for $9.1B

DOGE set to­day as their last day at FDA. In­stead, they're con­tin­u­ing to get full pay and don't work

sponsored

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py ...

A service from the Financial Times